Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools GIST

GIST

Programs, trials, and reported response and survival for gastrointestinal stromal tumor.

Data as of 11.07.2026

All drugs

Avapritinib

Ayvakit

Stage Approved

Sponsor Blueprint Medicines

Route oral tablet

Modality small molecule

Class KIT/PDGFRA type I TKI

Mechanism kinase inhibitor; GIST label limited to PDGFRA exon 18, including D842V

Target KIT (TEC-0117)

Target PDGFRA exon 18 (D842V)

Sources

fda, as of 2026-11-07

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=645c887c-8cd4-4623-8da9-ac223d71a8b9

Overall Response Rate (95% CI) 84% (69%, 93%) 89% (75%, 97%) ... PDGFRA exon 18 N = 43, PDGFRA D842V N = 38 ... Gastrointestinal Stromal Tumors Intracranial hemorrhage occurred in 3 of 267 patients (1.1%).

Ayvakit USPI section 1.1, 5.1 and 14.1, Table 10, NAVIGATOR (NCT02508532)

publication, as of 2026-11-07

https://pubmed.ncbi.nlm.nih.gov/34343033/

Median PFS was not statistically different between avapritinib and regorafenib (hazard ratio, 1.25; 95% CI, 0.99 to 1.57; 4.2 v 5.6 months; P = .055) ... Objective response rates were 17.1% and 7.2%

Kang YK et al. J Clin Oncol 2021;39:3128-3139, PMID 34343033, abstract

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT02508532

A Phase 1 Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT03465722

An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

Studies

NAVIGATOR

Registry NCT02508532

Phase Phase 1

Status Completed

Enrollment 250

Start 2015-08

Primary completion 2020-03-06

Study completion 2021-06-03

Avapritinib 300 or 400 mg, PDGFRA exon 18

Dose 300 or 400 mg

Regimen once daily

Population unresectable or metastatic GIST with PDGFRA exon 18 mutation (n = 43)

Estimand Single arm

overall response rate (independent review): 84%, median follow up 10.6 months

Avapritinib, PDGFRA D842V subgroup

Dose 300 or 400 mg

Regimen once daily

Population PDGFRA D842V (n = 38)

Estimand Single arm

overall response rate (independent review): 89%, median follow up 10.6 months

Avapritinib, all GIST safety population

Dose 300 or 400 mg

Regimen once daily

Population GIST, 267 patients in intracranial hemorrhage pooled count

Estimand Single arm

intracranial hemorrhage: 1.1%, label pooled GIST

VOYAGER

Registry NCT03465722

Phase Phase 3

Status Completed

Enrollment 476

Start 2018-03-26

Primary completion 2020-03-09

Study completion 2021-09-15

Avapritinib 300 mg

Dose 300 mg

Regimen once daily

Comparator regorafenib 160 mg

Population 3L or later GIST (n = 240)

Estimand ITT

median progression-free survival: 4.2 months, primary analysis

progression-free survival hazard ratio vs regorafenib: 1.25 HR, primary analysis; P = .055

objective response rate: 17.1%, primary analysis

Regorafenib 160 mg

Dose 160 mg

Regimen 3 weeks on 1 off

Population 3L or later GIST (n = 236)

Estimand ITT

median progression-free survival: 5.6 months, primary analysis

objective response rate: 7.2%, primary analysis